Pfizer (PFE) Shares Outstanding (2009 - 2026)
Pfizer (PFE) posted quarterly Shares Outstanding (Entity) of $5.7 billion for Q1 2026, little changed year-over-year from $5.7 billion in Q1 2025, and little changed quarter-over-quarter from $5.7 billion in Q4 2025.
Pfizer (PFE) Shares Outstanding (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Shares Outstanding (Entity) for 18 consecutive years, with $5.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) changed 0.28% year-over-year to $5.7 billion; the TTM figure through Mar 2026 stood at $5.7 billion (changed 0.28% YoY), while the FY2025 annual figure was $5.7 billion, changed 0.34% from the prior year.
- Shares Outstanding (Entity) held at $5.7 billion in Q1 2026 per PFE's latest filing, from $5.7 billion in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $5.7 billion in Q1 2026 and bottomed at $5.6 billion in Q3 2022.
- Historically, Shares Outstanding (Entity) has averaged $5.7 billion across 5 years, with a median of $5.7 billion in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) declined 0.09% — and 2023, when it gained 0.95%.
- Pfizer's Shares Outstanding (Entity) stood at $5.6 billion in 2022, then gained by 0.62% to $5.6 billion in 2023, then grew by 0.37% to $5.7 billion in 2024, then rose by 0.34% to $5.7 billion in 2025, then climbed by 0.14% to $5.7 billion in 2026.
- Business Quant data shows PFE's Shares Outstanding (Entity) at $5.7 billion in Q1 2026, $5.7 billion in Q4 2025, and $5.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 5.70 Bn |
| Mar 29, 2026 | 5.69 Bn |
| Dec 31, 2025 | 5.68 Bn |
| Sep 28, 2025 | 5.69 Bn |
| Jun 29, 2025 | 5.69 Bn |
| Mar 30, 2025 | 5.68 Bn |
| Dec 31, 2024 | 5.66 Bn |
| Sep 29, 2024 | 5.67 Bn |
| Jun 30, 2024 | 5.67 Bn |
| Mar 31, 2024 | 5.66 Bn |
| Dec 31, 2023 | 5.64 Bn |
| Sep 30, 2023 | 5.65 Bn |
| Jul 2, 2023 | 5.65 Bn |
| Apr 2, 2023 | 5.63 Bn |
| Dec 31, 2022 | 5.61 Bn |
| Sep 30, 2022 | 5.59 Bn |
| Jul 3, 2022 | 5.59 Bn |
| Apr 3, 2022 | 5.62 Bn |
| Dec 31, 2021 | 5.60 Bn |
| Oct 3, 2021 | 5.61 Bn |